Oppenheimer Assumes Innoviva at Outperform, Announces Price Target of $35

Benzinga Newsdesk www.benzinga.com Positive 52.5%

Neg 0% Neu 0% Pos 52.5%

Oppenheimer analyst Les Sulewski assumes Innoviva (NASDAQ:INVA) with a Outperform rating and announces Price Target of $35.